Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

7 lipca 2022 zaktualizowane przez: Hoosier Cancer Research Network

Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors

The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

OUTLINE: This is a multi-center study.

Phase I: Patients will be accrued in the classic 3 patients per dose per cohort design, 21-day cycle

  • Dose Level 1 Everolimus 10 mg BNC105P 4.2 mg/m2
  • Dose Level 2 Everolimus 10 mg BNC105P 8.4 mg/m2
  • Dose Level 3 Everolimus 10 mg BNC105P 12.6 mg/m2
  • Dose Level 4 Everolimus 10 mg BNC105P 16 mg/m2

Phase II: Patients will be randomized 1:1 to Arm A or Arm B

Combination Arm A: Everolimus 10 mg + BNC105P MTD (from Phase 1 study) 21 day cycle

Sequential Arm B: Everolimus 10 mg 21 day cycle

  • Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy.

Karnofsky Performance Score (KPS) ≥70 within 7 days prior to registration for protocol therapy.

Life Expectancy: Not specified

Hematopoietic:

  • White blood cell count (WBC) > 3.5 K/mm3
  • Hemoglobin (Hgb) > 8.5 g/dL
  • Platelets > 100 K/mm3
  • Absolute neutrophil count (ANC) > 1.5 K/mm3

Hepatic:

  • Total Bilirubin < 1.25 x ULN
  • Aminotransferase (AST and ALT) < 2.5 x ULN

Renal:

  • Serum Creatinine < 2.5 x ULN (upper limit normal)

Cardiovascular:

  • No significant cardiovascular events within 6 months (CVA, CAD, peripheral arterial obstruction, arrhythmias, cardiac dysfunction) of registration for protocol therapy
  • No history of clinical CHF or LVEF <50% by Echo (or MUGA) within 30 days prior to registration for protocol therapy.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

154

Faza

  • Faza 2
  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Australia
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Royal Prince Alfred Hospital: Sydney Cancer Centre
      • Randwick, New South Wales, Australia, 2031
        • Prince of Wales Hospital
      • Wahroonga, New South Wales, Australia, 2076
        • Sydney Adventist Hospital Ltd.
    • Queensland
      • Greenslopes, Queensland, Australia, 4120
        • Gallipoli Medical Research Foundation: Greenslopes Private Hospital
      • Herston, Queensland, Australia, 4029
        • Royal Brisbane & Women's Hospital
      • Woolloongabba, Queensland, Australia, 4201
        • Princess Alexandra Hospital
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Royal Adelaide Hospital
      • Kurralta Park, South Australia, Australia, 5037
        • Ashford Cancer Centre
    • Tasmania
      • Launceston, Tasmania, Australia, 7250
        • Gallipoli Medical Research Foundation: Launceston General Hospital
    • Victoria
      • Frankston, Victoria, Australia, 3199
        • Peninsula Oncology Centre
      • Heidelberg, Victoria, Australia, 3084
        • Austin Hospital
      • Melbourne, Victoria, Australia, 3004
        • Alfred Hospital
    • Western Australia
      • Perth, Western Australia, Australia, 6000
        • Royal Perth Hospital
  • Singapur
      • Singapore, Singapur, 169610
        • National Cancer Centre Singapore
  • Stany Zjednoczone
    • Alabama
      • Muscle Shoals, Alabama, Stany Zjednoczone, 35661
        • Northwest Alabama Cancer Center
    • Arkansas
      • Hot Springs, Arkansas, Stany Zjednoczone, 71913
        • Genesis Cancer Center
    • California
      • Burbank, California, Stany Zjednoczone, 91505
        • Providence Health System: Roy and Patricia Disney Family Cancer Center
      • Corona, California, Stany Zjednoczone, 92879
        • Compassionate Cancer Care Medical Group, Inc.
      • Corona, California, Stany Zjednoczone, 92879
        • Compassionate Cancer Care Medical Group
      • Duarte, California, Stany Zjednoczone, 91010
        • City of Hope
      • Fountain Valley, California, Stany Zjednoczone, 92708
        • Robert A. Moss, M.D., FACP, Inc.
      • Fresno, California, Stany Zjednoczone, 93720
        • California Cancer Associates for Research and Excellence
      • Greenbrae, California, Stany Zjednoczone, 94904
        • Marin Specialty Care
      • Los Angeles, California, Stany Zjednoczone, 90017
        • Good Samaritan Hospital
      • Los Angeles, California, Stany Zjednoczone, 90095
        • UCLA Med - Hematology & Oncology
      • Riverside, California, Stany Zjednoczone, 92501
        • Compassionate Cancer Care Medical Group
      • Whittier, California, Stany Zjednoczone, 90603
        • American Institute of Research
    • Colorado
      • Denver, Colorado, Stany Zjednoczone, 80210
        • Centura Health Research Center
      • Golden, Colorado, Stany Zjednoczone, 80401
        • Western Oncology & Hematology
    • Florida
      • Brooksville, Florida, Stany Zjednoczone, 34613
        • Cancer Care Centers of Florida: Brooksville
      • Fort Lauderdale, Florida, Stany Zjednoczone, 33308
        • Broward Oncology Associates
      • Gainesville, Florida, Stany Zjednoczone, 32610
        • University of Florida, Shands Cancer Center
      • Jacksonville, Florida, Stany Zjednoczone, 32256
        • Cancer Specialists of North Florida
      • Miami, Florida, Stany Zjednoczone, 33136
        • Advanced Pharma CR, LLC
      • New Port Richey, Florida, Stany Zjednoczone, 34652
        • Cancer Care Centers of Florida
      • Ocala, Florida, Stany Zjednoczone, 34471
        • Ocala Cancer Institute
      • Rockledge, Florida, Stany Zjednoczone, 32955
        • Cancer Care Centers of Brevard
    • Georgia
      • Athens, Georgia, Stany Zjednoczone, 30607
        • Northeast Georgia Cancer Care, LLC
      • Dublin, Georgia, Stany Zjednoczone, 31021
        • Dublin Hematology & Oncology Care
    • Idaho
      • Post Falls, Idaho, Stany Zjednoczone, 83854
        • Kootenai Cancer Center
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60611
        • Northwestern University, Robert H. Lurie Comprehensive Cancer Center
      • Galesburg, Illinois, Stany Zjednoczone, 61401
        • Medical & Surgical Specialists, LLC
      • Skokie, Illinois, Stany Zjednoczone, 60076
        • Edward H. Kaplan, M.D., & Associates
    • Indiana
      • Evansville, Indiana, Stany Zjednoczone, 47713
        • Deaconess Clinic
      • Fort Wayne, Indiana, Stany Zjednoczone, 46815
        • Fort Wayne Oncology & Hematology, Inc
      • Goshen, Indiana, Stany Zjednoczone, 46527
        • IU Health Goshen
      • Indianapolis, Indiana, Stany Zjednoczone, 46202
        • Indiana University Melvin and Bren Simon Cancer Center
      • Indianapolis, Indiana, Stany Zjednoczone, 46219
        • IU Health Central Indiana Cancer Centers
      • Indianapolis, Indiana, Stany Zjednoczone, 46256
        • Community Regional Cancer Center
      • Lafayette, Indiana, Stany Zjednoczone, 47905
        • Horizon Oncology Research
      • Muncie, Indiana, Stany Zjednoczone, 47303
        • IU Health at Ball Memorial Hospital Cancer Center
      • Munster, Indiana, Stany Zjednoczone, 46321
        • Monroe Medical Associates
      • Newburgh, Indiana, Stany Zjednoczone, 47630
        • Oncology Hematology Associates of SW Indiana
      • South Bend, Indiana, Stany Zjednoczone, 46601
        • Northern Indiana Cancer Research Consortium
    • Iowa
      • Sioux City, Iowa, Stany Zjednoczone, 51101
        • Siouxland Hematology Oncology Associates, LLP, Nylen Cancer Center
    • Kansas
      • Wichita, Kansas, Stany Zjednoczone, 67214
        • Cancer Center of Kansas
    • Kentucky
      • Hazard, Kentucky, Stany Zjednoczone, 41701
        • Kentucky Cancer Clinic
      • Paducah, Kentucky, Stany Zjednoczone, 42001
        • Purchase Cancer Group
    • Louisiana
      • Baton Rouge, Louisiana, Stany Zjednoczone, 70809
        • Medical Oncology LLC
      • Metairie, Louisiana, Stany Zjednoczone, 70006
        • Metairie Oncologists
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02111
        • Tufts Medical Center
    • Michigan
      • Ann Arbor, Michigan, Stany Zjednoczone, 48106
        • St. Joseph Mercy Hospital
      • Grand Rapids, Michigan, Stany Zjednoczone, 49546
        • Cancer and Hematology Centers of Western Michigan
      • Wyoming, Michigan, Stany Zjednoczone, 49519
        • Metro Health Cancer Care
    • Minnesota
      • Rochester, Minnesota, Stany Zjednoczone, 55905
        • Mayo Clinic
    • Montana
      • Bozeman, Montana, Stany Zjednoczone, 59715
        • Bozeman Deaconness Cancer Center
      • Great Falls, Montana, Stany Zjednoczone, 59405
        • Sletten Cancer Specialists
    • Nebraska
      • Omaha, Nebraska, Stany Zjednoczone, 68114
        • Methodist Cancer Center
    • New Hampshire
      • Manchester, New Hampshire, Stany Zjednoczone, 03102
        • Dartmouth-Hitchcock Medical Center
    • New Jersey
      • Elizabeth, New Jersey, Stany Zjednoczone, 07202
        • Trinitas Regional Medical Center
      • Somerville, New Jersey, Stany Zjednoczone, 08876
        • Somerset Hematology Oncology Associates
    • New Mexico
      • Albuquerque, New Mexico, Stany Zjednoczone, 87110
        • Presbyterian Medical Group
      • Albuquerque, New Mexico, Stany Zjednoczone, 87131
        • University of New Mexico Cancer Center: Albuquerque
    • New York
      • Albany, New York, Stany Zjednoczone, 12208
        • New York Oncology Hematology, PC
      • Buffalo, New York, Stany Zjednoczone, 14263
        • Roswell Park Cancer Institute
      • Lake Success, New York, Stany Zjednoczone, 11042
        • NYU Langone Arena Oncology
      • New York, New York, Stany Zjednoczone, 10029
        • Tisch Cancer Institute at Mount Sinai Medical Center
      • Nyack, New York, Stany Zjednoczone, 10960
        • Hematology Oncology Associates of Rockland
    • North Carolina
      • Pinehurst, North Carolina, Stany Zjednoczone, 28374
        • First Health of the Carolinas
    • Ohio
      • Middletown, Ohio, Stany Zjednoczone, 45042
        • Signal Point Clinical Research Center
      • Wooster, Ohio, Stany Zjednoczone, 44691
        • Lawrence M. Stallings, M.D.
    • Oklahoma
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73120
        • Mercy Physicians Of Oklahoma
    • Oregon
      • Springfield, Oregon, Stany Zjednoczone, 97477
        • Willamette Valley Cancer Institute
    • Pennsylvania
      • Danville, Pennsylvania, Stany Zjednoczone, 17822
        • Geisinger Medical Center
      • Gettysburg, Pennsylvania, Stany Zjednoczone, 17235
        • Gettysburg Cancer Center
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15212
        • Allegheny Cancer Center
      • State College, Pennsylvania, Stany Zjednoczone, 16803
        • Mount Nittany Medical Center
      • West Reading, Pennsylvania, Stany Zjednoczone, 19611
        • Berks Hematology Oncology Associates
    • Rhode Island
      • Cranston, Rhode Island, Stany Zjednoczone, 02920
        • Hematology and Oncology Associates of Rhode Island
    • South Carolina
      • Charleston, South Carolina, Stany Zjednoczone, 29425
        • MUSC Hollings Cancer Center
      • Hilton Head Island, South Carolina, Stany Zjednoczone, 29926
        • South Carolina Cancer Specialists
    • Tennessee
      • Germantown, Tennessee, Stany Zjednoczone, 38138
        • The Jones Clinic, PC
    • Texas
      • Austin, Texas, Stany Zjednoczone, 78758
        • Texas Oncology: Austin North
      • Bedford, Texas, Stany Zjednoczone, 76022
        • Texas Oncology: Bedford
      • Dallas, Texas, Stany Zjednoczone, 75246
        • Texas Oncology, PA
      • Fort Worth, Texas, Stany Zjednoczone, 76104
        • Texas Oncology: Fort Worth
      • Houston, Texas, Stany Zjednoczone, 77030
        • Methodist Hospital Research Institute
      • Houston, Texas, Stany Zjednoczone, 77024
        • Texas Oncology: Houston Memorial City
      • Houston, Texas, Stany Zjednoczone, 77055
        • Houston Cancer Center
      • Lubbock, Texas, Stany Zjednoczone, 79410
        • Joe Arrington Cancer Research and Treatment Center
      • San Antonio, Texas, Stany Zjednoczone, 78229
        • CTRC at the UT Health Science Center at San Antonio
    • Virginia
      • Lynchburg, Virginia, Stany Zjednoczone, 24501
        • Lynchburg Hematology Oncology Clinic, Inc.
    • Washington
      • Bremerton, Washington, Stany Zjednoczone, 98310
        • Harrison HealthPartners Bremerton Hematology & Oncology
      • Kirkland, Washington, Stany Zjednoczone, 98034
        • Cascade Cancer Center
      • Seattle, Washington, Stany Zjednoczone, 98109
        • University of Washington, Seattle Cancer Care Alliance
      • Seattle, Washington, Stany Zjednoczone, 98109
        • Group Health Medical Centers
      • Spokane, Washington, Stany Zjednoczone, 99204
        • Rockwood Clinic
    • Wisconsin
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53226
        • University of Wisconsin, Clinical Cancer Center

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Histological or cytological proof of component (any percent) of clear cell RCC (renal cell carcinoma).
  • Metastatic or locally advanced unresectable RCC. NOTE: Prior nephrectomy is not mandatory.
  • Progressive disease after 1-2 prior VEGF-directed tyrosine kinase inhibitors (TKIs).
  • Measurable disease according to RECIST and obtained by imaging within 30 days prior to registration for protocol therapy.
  • Written informed consent and HIPAA authorization for release of personal health information.
  • Age > 18 years at the time of consent.
  • Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 4 weeks after treatment discontinuation.
  • Females of childbearing potential must have a negative pregnancy test within 7 days prior to registration for protocol therapy.

Exclusion Criteria:

  • No active brain metastases. Patients with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis within 30 days prior to registration on protocol therapy. NOTE: A patient with prior brain metastasis are eligible if they have completed their radiation treatment for brain metastasis ≥30 days prior to registration for protocol therapy, are off steroids, and are asymptomatic.
  • No other currently active malignancy.
  • No treatment with any investigational agent within 14 days prior to registration for protocol therapy. NOTE: If treated with investigational agent within 14 days prior to registration, AE must be resolved back to baseline.
  • Prior cancer treatment must be completed at least 14 days prior to registration for protocol therapy and the patient must have recovered from the acute toxic effects of the regimen. With the exception of Bevacizumab treatment, which must be completed 30 days prior to registration for protocol therapy.
  • Prior radiation therapy to < 25% of the bone marrow [see bone marrow radiation chart in the study procedure manual (SPM)] allowed if completed within 30 days prior to registration for protocol therapy.
  • Corrected QT interval (QTc) ≤ 450 msec at least 7 days prior to registration for protocol therapy.
  • No clinically significant infections as judged by the treating investigator.
  • No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
  • No collecting duct, medullary or sarcomatoid histology.
  • No prior treatment with temsirolimus or everolimus in the phase II component of the study. NOTE: Prior treatment with these agents is permitted in the phase I component of the study.
  • No use of full dose, therapeutic anti-coagulation with warfarin or related anti-coagulants or unfractionated or low molecular weight heparins.
  • No uncontrolled hypertension (BP >150/100mmHg despite full doses of 1 anti-hypertensive medication).
  • No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of registration for protocol therapy.
  • No grade 2 or greater peripheral neuropathy.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Combination Arm A: Everolimus + BNC105P
Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
Lek: Everolimus
Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
Lek: BNC105P
BNC105P, up to 16 mg/m^2
Aktywny komparator: Sequential Arm B:Everolimus followed by BNC105P Monotherapy

Sequential Arm B: Everolimus 10 mg, 21 day cycle

Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy.
Lek: Everolimus
Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
Lek: BNC105P
BNC105P, up to 16 mg/m^2

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Phase I: Maximum Tolerated Dose of BNC105P in Combination With Everolimus.
Ramy czasowe: Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
Phase I
Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
Phase I: Toxicities of BNC105P in Combination With Everolimus.
Ramy czasowe: Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
Determine the toxicities of BNC105P in combination with everolimus. Drug-related treatment emergent adverse events by CTCAE grade 2 or greater are reported
Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
Phase II: 6-month Progression Free Survival (PFS) With the Addition of BNC105P to Everolimus.
Ramy czasowe: 6 months
Improvement in 6-month PFS with the addition of BNC105P to everolimus. Progression is defined using RECIST criteria as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions
6 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Phase I: Response Rate of BNC105P in Combination With Everolimus.
Ramy czasowe: Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
Number of objective responses per RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
Geometric Mean Half-life of BNC105 and BNC105P in Combination With Everolimus.
Ramy czasowe: 12 months
Determine the PK Profile for BN105P in combination with everolimus by calculating the geometric mean half-life of BNC105P
12 months
Phase II: Response Rate With Combination Therapy Compared to Everolimus Alone
Ramy czasowe: 12 months
Objective response is defined as a confirmed CR or PR per RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
12 months
Phase II: Progression Free Survival (PFS) With BNC105P Alone in Patients After Progressing on Everolimus.
Ramy czasowe: 12 months
Median time to progression for arm P participants who crossed over to BNC105P monotherapy after progression. Progression is defined per RECIST criteria as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions
12 months
Phase II: Adverse Events of Everolimus and BNC105P When Administered as a Combination or Sequential Regimen.
Ramy czasowe: 12 months
Determine adverse events of everolimus and BNC105P when administered as a combination or sequential regimen. Total number of serious and non-serious adverse events for Arm A and Arm B are summarized. Complete adverse event information is supplied in the Adverse Events reporting section.
12 months
Phase II: Overall Survival
Ramy czasowe: 60 months
Determine overall survival probability, up to a maximum of 5 years from registration for protocol therapy.
60 months
Exploratory Objective: Correlation of PFS With Biomarkers
Ramy czasowe: 6 months
Exploratory analysis of serum biomarkers were undertaken to generate a potential signature for response. The correlation with 6 month progression free survival P value for four plasma biomarkers is reported.
6 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Hoosier Cancer Research Network

Współpracownicy

Bionomics Limited

Śledczy

  • Krzesło do nauki: Thomas Hutson, D.O., Hoosier Cancer Research Network

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 stycznia 2010

Zakończenie podstawowe (Rzeczywisty)

1 grudnia 2016

Ukończenie studiów (Rzeczywisty)

1 grudnia 2016

Daty rejestracji na studia

Pierwszy przesłany

15 grudnia 2009

Pierwszy przesłany, który spełnia kryteria kontroli jakości

15 grudnia 2009

Pierwszy wysłany (Oszacować)

17 grudnia 2009

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

11 lipca 2022

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

7 lipca 2022

Ostatnia weryfikacja

1 kwietnia 2017

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • HOG GU09-145

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Rak nerkowokomórkowy

Badania kliniczne na Everolimus

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Vietnam

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj